CA2593122A1 - Anti a beta antibody formulation - Google Patents

Anti a beta antibody formulation Download PDF

Info

Publication number
CA2593122A1
CA2593122A1 CA002593122A CA2593122A CA2593122A1 CA 2593122 A1 CA2593122 A1 CA 2593122A1 CA 002593122 A CA002593122 A CA 002593122A CA 2593122 A CA2593122 A CA 2593122A CA 2593122 A1 CA2593122 A1 CA 2593122A1
Authority
CA
Canada
Prior art keywords
antibody
formulation
beta
humanized
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002593122A
Other languages
French (fr)
Other versions
CA2593122C (en
Inventor
Donna Luisi
Nicholas W. Warne
Angela Kantor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland UC
Wyeth LLC
Original Assignee
Neuralab Limited
Wyeth
Donna Luisi
Nicholas W. Warne
Angela Kantor
Elan Pharma International Limited
Crimagua Limited
Janssen Alzheimer Immunotherapy
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuralab Limited, Wyeth, Donna Luisi, Nicholas W. Warne, Angela Kantor, Elan Pharma International Limited, Crimagua Limited, Janssen Alzheimer Immunotherapy, Wyeth Llc filed Critical Neuralab Limited
Publication of CA2593122A1 publication Critical patent/CA2593122A1/en
Application granted granted Critical
Publication of CA2593122C publication Critical patent/CA2593122C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

The present invention provides formulations for maintaining the stability of A.beta. binding polypeptides, for example, A.beta. antibodies. Exemplary formulations include a tonicity agent such as mannitol and a buffering agent or amino acid such as histidine. Other exemplary formulations include an antioxidant in a sufficient amount as to inhibit by-product formation, for example, the formation of high molecular weight polypeptide aggregates, low molecular weight polypeptide degradation fragments, and mixtures thereof. The formulations of the invention optionally comprise a tonicity agent, such as mannitol, and a buffering agent or amino acid such as histidine. The formulations are suitable for several different routes of administration.

Claims (86)

1. A stabilized formulation comprising at least one A.beta. binding polypeptide, at least one tonicity agent, wherein the tonicity agent is present in an amount sufficient to render the formulation suitable for administration, and at least one buffering agent in an amount sufficient to maintain a physiologically suitable pH.
2. The formulation of claim 1, further comprising at least one antioxidant.
3. The formulation of claim 2, wherein at least one antioxidant is methionine.
4. The formulation of claim 1, wherein at least one tonicity agent is mannitol.
5. The formulation of claim 4, wherein at least one tonicity agent is NaCl.
6. The formulation of claim 1, wherein at least one buffering agent is histidine.
7. The formulation of claim 1, wherein at least one buffering agent is succinate.
8. The formulation of claim 1, wherein at least one buffering agent is sodium phosphate.
9. The formulation of claim 1, further coinprising at least one stabilizer.
10. The formulation of claim 9, wherein at least one stabilizer is polysorbate 80.
11. The formulation of claim 1, wherein at least one A.beta. binding polypeptide is selected from the group consisting of an anti A.beta. antibody, an anti A.beta. antibody Fv fragment, an anti A.beta. antibody Fab fragment, an anti A.beta. antibody Fab'(2) fragment, an anti A.beta. antibody Fd fragment, a single-chain anti A.beta.
antibody (scFv), a single domain anti A.beta. antibody fragment (Dab), a beta-pleated sheet polypeptide comprising at least one antibody complementarity determining region (CDR) from an anti A.beta. antibody, and a non-globular polypeptide comprising at least one antibody CDR from an anti A.beta. antibody.
12. The formulation of claim 11, wherein at least one A.beta. binding polypeptide is an anti A.beta. antibody.
13. The formulation of claim 12, wherein the anti A.beta. antibody specifically binds to an epitope within residues selected from the group consisting of 1-7, 1-5, 3-7, 3-6, 13-28, 15-24, 16-24, 16-21, 19-22, 33-40, and 33-42 of A.beta..
14. The formulation of claim 13, wherein the anti A.beta. antibody specifically binds to an epitope within residues 1-7.
15. The formulation of claim 13, wherein the anti A.beta. antibody specifically binds to an epitope within residues 1-5.
16. The formulation of claim 13, wherein the anti A.beta. antibody specifically binds to an epitope within residues 3-6.
17. The formulation of claim 13, wherein the anti A.beta. antibody specifically binds to an epitope within residues 3-7.
18. The formulation of claim 13, wherein the anti A.beta. antibody specifically binds to an epitope within residues 13-28.
19. The formulation of claim 13, wherein the anti A.beta. antibody specifically binds to an epitope within residues 16-24.
20. The formulation of claim 13, wherein the anti A.beta. antibody specifically binds to an epitope within residues 16-21.
21. The formulation of claim 13, wherein the anti A.beta. antibody specifically binds to an epitope within residues 19-22.
22. The formulation of claim 12, wherein the anti A.beta. antibody is selected from the group consisting of a humanized 3D6 antibody, a humanized 10D5 antibody, a humanized 12B4 antibody, a humanized 266 antibody, a humanized 12A11 antibody, and a humanized 15C11 antibody.
23. The formulation of claim 22, further comprising a stabilizer and an antioxidant.
24. The formulation of claim 23, wherein the stabilizer is polysorbate 80, the antioxidant is methionine, the tonicity agent is mannitol, sorbitol or NaC1, and the buffering agent is histidine.
25. The formulation of claim 22, wherein the formulation is a lyophilized formulation.
26. The formulation of claim 22, wherein the formulation is a liquid formulation.
27. The formulation of claim 22, wherein the antibody is of isotype human IgG1.
28. The formulation of claim 22, wherein the antibody is of isotype human IgG4.
29. The formulation of claim 12, wherein the anti A.beta. antibody is present at a concentration of about 0.1 mg/ml to about 60 mg/ml.
30. The formulation of claim 12, wherein the anti A.beta. antibody is present at a concentration of about 20 mg/ml.
31. The formulation of claim 12, wherein the anti A.beta. antibody is present at a concentration of about 10 mg/ml.
32. The formulation of claim 23, wherein at least one tonicity agent is D-mannitol at a concentration of about 1% w/v to about 10% w/v.
33. The formulation of claim 32, wherein the concentration of D-mannitol is about 2% w/v to about 6% w/v.
34. The formulation of claim 23, wherein at least one buffering agent is histidine at a concentration of about 0.1 mM to about 25 mM.
35. The formulation of claim 23, wherein the formulation has a pH of about 5.5 to about 6.5.
36. The formulation of claim 22, wherein the anti A.beta. antibody is a humanized 3D6 antibody.
37. The formulation of claim 22, wherein the anti A.beta. antibody is a humanized 12A11 antibody.
38. The formulation of claim 22, wherein the anti A.beta. antibody is a humanized 266 antibody.
39. The formulation of claim 22, wherein the anti A.beta. antibody is a humanized 15C11 antibody.
40. A formulation stable for at least about 12 months at a temperature of above freezing to about 10°C and having a pH of about 5.5 to about 6.5, comprising:

i. at least one A.beta. antibody at a concentration of about 1 mg/ml to about 30 mg/ml;

ii. mannitol at a concentration of about 4% w/v or NaCl at a concentration of about 150 mM;

iii. about 5 mM to about 10 mM histidine or succinate; and iv. 10 mM methionine.
41. The formulation of claim 40, wherein the formulation is stable for at least about 24 months at a temperature of about 2°C to 8°C, and comprises polysorbate 80 at a concentration of about 0.001 % w/v to about 0.01 % w/v.
42. The formulation of claim 40, wherein the formulation has a pH of about 6.0 to about 6.5 and comprises about 10 mg/ml A.beta. antibody, about 10 mM histidine and about 4% w/v mannitol and about .005% w/v polysorbate 80.
43. The formulation of claim 40, wherein the formulation has a pH of about 6.0 to about 6.2 and comprises about 20 mg/ml A.beta. antibody, about 10 mM
histidine, about 4% w/v mannitol and about .005% w/v polysorbate 80.
44. The formulation of claim 40, wherein the formulation has a pH of about 6.0 to about 6.2 and comprises about 30 mg/ml A.beta. antibody, about 10 mM
histidine, about 4% w/v mannitol and about .005% w/v polysorbate 80.
45. The formulation of claim 40, wherein the A.beta. antibody is selected from the group consisting of a humanized 3D6 antibody, a humanized 10D5 antibody, a humanized 12B4 antibody, a humanized 266 antibody, a humanized 12A11 antibody, and a humanized 15C11 antibody.
46. The formulation of claim 40, wherein the formulation has a pH of about 6.0 to 6.5 and comprises about 10 mM histidine, about 4% w/v mannitol and about 2 mg/ml to about 20 mg/ml of an A.beta. antibody selected from the group consisting of a humanized 3D6 antibody, a humanized 10D5 antibody, a humanized 12B4 antibody, and a humanized 12A11 antibody.
47. The formulation of claim 40, wherein the formulation has a pH of about 6.0 to 6.5 and comprises about 10 mM histidine, about 150 mM NaCl and about 2 mg/ml to about 20 mg/ml of an A.beta. antibody selected from the group consisting of a humanized 12B4 antibody, and a humanized 12A11 antibody.
48. The formulation of claim 40, wherein the formulation has a pH of about 6.0 to 6.5 and comprises about 10 mM histidine, about 4% w/v mannitol and about 2 mg/ml to about 20 mg/ml of an A.beta. antibody selected from the group consisting of a humanized 266 antibody and a humanized 15C11 antibody.
49. A formulation stable for at least about 24 months at a temperature of about 2°C
to about 8°C and having a pH of about 5.5 to about 6.5, comprising about 2 mg/ml to about 23 mg/ml of a humanized 3D6 antibody, about 10 mM histidine and about 10 mM methionine.
50. The formulation of claim 49, further comprising about 4% w/v mannitol.
51. The formulation of claim 49, further comprising polysorbate 80 at a concentration of about 0.001% w/v to about 0.01 % w/v.
52. The formulation of claim 51, comprising about 0.005% w/v polysorbate 80.
53. The formulation of claim 49, wherein the humanized 3D6 antibody is present at a concentration of about 17 mg/ml to about 23 mg/ml.
54. A formulation stable for at least about 24 months at a temperature of about 2°C to about 8°C and having a pH of about 5.5 to about 6.5, comprising about 2 mg/ml to about 23 mg/ml of a humanized 3D6 antibody, about 10 mM succinate, about 10 mM methionine, about 4% w/v mannitol and about 0.005% w/v polysorbate 80.
55. A formulation stable for at least about 24 months at a temperature of about 2°C to about 8°C and having a pH of about 6.0 to about 6.5, comprising about 2 mg/ml to about 30 mg/ml of a humanized 266 antibody, about 10 mM histidine and about 10 mM methionine.
56. The formulation of claim 55, further comprising about 4% w/v mannitol.
57. The formulation of claim 55, further comprising polysorbate 80 at a concentration of about 0.001% w/v to about 0.01% w/v.
58. A formulation stable for at least about 24 months at a temperature of about 2°C to about 8°C and having a pH of about 6.0 to about 6.5, comprising about 2 mg/ml to about 30 mg/ml of a humanized 12A11 antibody, about 10 mM histidine and about mM methionine.
59. The formulation of claim 58, further comprising about 150 mM NaCl.
60. The formulation of claim 58, further comprising polysorbate 80 at a concentration of about 0.001% w/v to about 0.01% w/v.
61. A formulation stable for at least about 24 months at a temperature of about 2°C to about 8°C and having a pH of about 6.0 to about 6.5, comprising about 2 mg/ml to about 20 mg/ml of a humanized 12A11 antibody, about 5 mM histidine, about 10 mM methionine, about 4% w/v mannitol and about 0.005% w/v polysorbate 80.
62. A formulation stable when thawed from about -50°c to about -80°c, comprising about 40 to about 60 mg/ml of an anti A.beta. antibody, about 1.0 mg/ml to about 2.0 mg/ml histidine, about 1.0mg/ml to 2.0 mg/ml methionine and about 0.05 mg/ml polysorbate 80, wherein the formulation has a pH of about 6Ø
63. The formulation of claim 62, wherein mannitol is excluded.
64. The formulation of claim 63, wherein the A.beta. antibody is a humanized antibody.
65. The formulation of claim 63, wherein the A.beta. antibody is a humanized antibody.
66. A formulation comprising about 20 mg/mL anti A.beta. antibody, about 10 mM
L-histidine, about 10 mM methionine, about 4% mannitol and having a pH of about 6.
67. A formulation comprising about 30 mg/mL anti A.beta. antibody, about 10 mM

succinate, about 10 mM methionine, about 6% mannitol and having a pH of about 6.2.
68. A formulation comprising about 20 mg/mL anti A.beta. antibody, about 10 mM
L-histidine, about 10 mM methionine, about 4% mannitol, about 0.005% polysorbate 80, and having a pH of about 6.
69. A formulation comprising about 10 mg/mL anti A.beta. antibody, about 10 mM

succinate, about 10 mM methionine, about 10% mannitol, about 0.005%
polysorbate 80, and having a pH of about 6.5.
70. A formulation comprising about 5 mg/mL to about 20 mg/mL anti A.beta.
antibody, about 5 mM to about 10 mM L-histidine, about 10 mM methionine, about 4%
mannitol, about 0.005% polysorbate 80, and having a pH of about 6.0 to about 6.5.
71. A formulation comprising about 5 mg/mL to about 20 mg/mL anti A.beta.
antibody, about 5 mM to about 10 mM L-histidine, about 10 mM methionine, about 150 mM
NaCl, about 0.005% polysorbate 80, and having a pH of about 6.0 to about 6.5.
72. A pharmaceutical unit dosage form, comprising a formulation comprising:

a. about 10 mg to about 250 mg of an anti A.beta. antibody;
b. about 4% mannitol or about 150 mM NaCl;

c. about 5 mM to about 10 mM histidine or succinate; and d. about 10 mM methionine.
73. The pharmaceutical unit dosage form of claim 72, comprising about 0.001%
to about 0.1% polysorbate 80.
74. The pharmaceutical unit dosage form of claim 73, comprising about 40 mg to about 60 mg of the anti A.beta. antibody.
75. The pharmaceutical unit dosage form of claim 73, comprising about 60 mg to about 80 mg of the anti A.beta. antibody.
76. The pharmaceutical unit dosage form of claim 73, comprising about 80 mg to about 120 mg of the anti A.beta. antibody.
77. The pharmaceutical unit dosage form of claim 73, comprising about 120 mg to about 160 mg of the anti A.beta. antibody.
78. The pharmaceutical unit dosage form of claim 73, comprising about 160 mg to about 240 mg of the anti A.beta. antibody.
79. A therapeutic product, comprising:

a. a glass vial, comprising a formulation comprising:

i. about 10 mg to about 250 mg of a humanized anti A.beta.
antibody, ii. about 4% mannitol or about 150 mM NaCl, iii. about 5 mM to about 10 mM histidine, and iv. about 10 mM methionine; and b. labeling for use comprising instructions to use the appropriate volume necessary to achieve a dose of about 0.15 mg/kg to about mg/kg.
80. The therapeutic product of claim 79, wherein the dose is about .5 mg/kg to about 3 mg/kg.
81. The therapeutic product of claim 79, wherein the dose is about 1 mg/kg to about 2 mg/kg.
82. The therapeutic product of claim 79, wherein the anti A.beta. antibody concentration is about 10 mg/ml to about 60 mg/ml.
83. The therapeutic product of claim 79, wherein the anti A.beta. antibody concentration is about 20 mg/ml.
84. The therapeutic product of claim 79, further comprising about 0.005%
polysorbate 80.
85. The therapeutic product of claim 79, wherein the use is a subcutaneous administration.
86. The therapeutic product of claim 79, wherein the use is an intravenous administration.
CA2593122A 2005-01-28 2006-01-27 Anti a beta antibody formulation Expired - Fee Related CA2593122C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64863105P 2005-01-28 2005-01-28
US60/648,631 2005-01-28
PCT/US2006/002837 WO2006083689A2 (en) 2005-01-28 2006-01-27 Anti a beta antibody formulation

Publications (2)

Publication Number Publication Date
CA2593122A1 true CA2593122A1 (en) 2006-08-10
CA2593122C CA2593122C (en) 2012-03-06

Family

ID=36686080

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2593122A Expired - Fee Related CA2593122C (en) 2005-01-28 2006-01-27 Anti a beta antibody formulation

Country Status (30)

Country Link
US (2) US7635473B2 (en)
EP (2) EP1853310B1 (en)
JP (1) JP4977625B2 (en)
KR (1) KR101188060B1 (en)
CN (2) CN103768009B (en)
AR (1) AR052198A1 (en)
AU (1) AU2006211184B8 (en)
BR (1) BRPI0607039A2 (en)
CA (1) CA2593122C (en)
DK (1) DK1853310T3 (en)
DO (1) DOP2006000021A (en)
EA (2) EA021507B1 (en)
ES (1) ES2391407T3 (en)
GT (1) GT200600031A (en)
HK (3) HK1108132A1 (en)
IL (1) IL184599A (en)
JO (1) JO2740B1 (en)
MX (1) MX2007009050A (en)
MY (1) MY177052A (en)
NO (1) NO20073305L (en)
NZ (1) NZ556393A (en)
PE (1) PE20060879A1 (en)
PL (1) PL1853310T3 (en)
PT (1) PT1853310E (en)
SI (1) SI1853310T1 (en)
TW (1) TWI398263B (en)
UA (1) UA87549C2 (en)
UY (1) UY29351A1 (en)
WO (1) WO2006083689A2 (en)
ZA (1) ZA200705710B (en)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
JP5362164B2 (en) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー Prevention and treatment of Alzheimer's disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
RU2390350C2 (en) * 2003-02-01 2010-05-27 Ньюралаб Лимитед Active immunisation for creating soluble a-beta antibodies
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US7807804B2 (en) * 2004-10-05 2010-10-05 Wyeth Llc Methods and compositions for improving recombinant protein production
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
GT200600031A (en) 2005-01-28 2006-08-29 ANTI-BETA ANTIBODY FORMULATION
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
UY29504A1 (en) 2005-04-29 2006-10-31 Rinat Neuroscience Corp DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME.
WO2006138553A2 (en) * 2005-06-17 2006-12-28 Wyeth Methods of purifying fc region containing proteins
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
KR20180058863A (en) 2005-11-30 2018-06-01 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
KR101591223B1 (en) 2005-12-12 2016-02-04 에이씨 이뮨 에스.에이. A beta 1-42 specific monoclonal antibodies with therapeutic properties
DK3219328T3 (en) * 2005-12-29 2020-07-13 Janssen Biotech Inc HUMANE ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND USES
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
WO2009017467A1 (en) * 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
WO2010044803A1 (en) * 2008-10-17 2010-04-22 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
PL2046833T3 (en) 2006-07-14 2014-01-31 Ac Immune Sa Humanized antibody against amyloid beta
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2094729A1 (en) * 2006-12-11 2009-09-02 F.Hoffmann-La Roche Ag Abeta antibody parenteral formulation
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CN101970000A (en) * 2007-04-18 2011-02-09 杨森阿尔茨海默氏症免疫治疗公司 Prevention and treatment of cerebral amyloid angiopathy
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CA2692165A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2009037190A2 (en) * 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
CA2701788C (en) * 2007-10-05 2017-06-13 Genentech, Inc. Humanized beta-amyloid antibody for treating ocular diseases
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
SI2238166T1 (en) 2007-10-05 2014-03-31 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (en) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
AU2016208353B2 (en) * 2007-10-17 2017-07-20 Janssen Alzheimer Immunotherapy Immunotherapy regimes dependent on ApoE status
KR101537460B1 (en) 2008-05-23 2015-07-16 시와 코퍼레이션 Methods, compositions and apparatus for facilitating regeneration
EP2310032A2 (en) * 2008-06-12 2011-04-20 Affiris AG Compounds for treating symptoms associated with parkinson's disease
US20100068210A1 (en) * 2008-09-10 2010-03-18 Ji Junyan A Compositions and methods for the prevention of oxidative degradation of proteins
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
SI3345615T1 (en) 2010-03-01 2020-03-31 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
JP5826194B2 (en) 2010-03-03 2015-12-02 アブリンクス ナームローゼ フェンノートシャップ Biparatopic A-beta binding polypeptide
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
MY164579A (en) 2010-07-30 2018-01-15 Ac Immune Sa Safe and functional humanized antibodies
CN103298833B (en) 2010-08-14 2015-12-16 Abbvie公司 Amyloid beta associated proteins
TW201213342A (en) * 2010-09-17 2012-04-01 Baxter Int Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral pH
JO3400B1 (en) * 2010-09-30 2019-10-20 Ferring Bv Pharmaceutical composition of carbetocin
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
EP2471554A1 (en) * 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
KR20140022845A (en) 2011-03-25 2014-02-25 제넨테크, 인크. Novel protein purification methods
EP2704751B1 (en) 2011-05-02 2019-04-17 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CN108969469A (en) * 2011-05-02 2018-12-11 米伦纽姆医药公司 The preparation of 4 β of anti alpha, 7 antibody
UY34105A (en) 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
PE20191242A1 (en) 2011-10-25 2019-09-16 Prothena Biosciences Ltd ANTIBODY FORMULATIONS AND METHODS
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (en) * 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh LIQUID FORMULATION THAT INCLUDES A GM-CSF NEUTRALIZING COMPOUND
UA117466C2 (en) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
WO2015028657A1 (en) 2013-08-30 2015-03-05 Takeda Gmbh Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
TWI694836B (en) * 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 Antibody formulation
WO2016005466A2 (en) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
WO2016065090A1 (en) 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US11091543B2 (en) * 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
AU2016257023B2 (en) * 2015-05-07 2022-06-30 Swedish Orphan Biovitrum Ag Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers
AR104847A1 (en) 2015-06-17 2017-08-16 Lilly Co Eli FORMULATION OF ANTI-CGRP ANTIBODY
RS62986B1 (en) 2015-06-24 2022-03-31 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
TWI747843B (en) 2015-10-02 2021-12-01 瑞士商赫孚孟拉羅股份公司 Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
ES2770787T3 (en) 2016-02-19 2020-07-03 Siwa Corp Method and composition for treating cancer, destroying metastatic cancer cells and preventing cancer metastasis using advanced glycation end-product antibody (AGE)
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
US11958900B2 (en) * 2016-04-15 2024-04-16 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
US11213585B2 (en) 2016-06-23 2022-01-04 Siwa Corporation Vaccines for use in treating various diseases and disorders
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
CN110352201A (en) 2017-04-03 2019-10-18 免疫医疗公司 The subcutaneous administration of antibody drug conjugate for cancer therapy
US10919957B2 (en) 2017-04-13 2021-02-16 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201909955XA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
IL272773B1 (en) * 2017-08-22 2024-02-01 Biogen Ma Inc Pharmaceutical compositions containing anti-beta amyloid antibodies
KR20200044066A (en) * 2017-08-22 2020-04-28 바이오젠 엠에이 인코포레이티드 Pharmaceutical compositions and dosing regimens containing anti-alpha (V) beta (6) antibodies
IL310113A (en) * 2017-09-19 2024-03-01 Regeneron Pharma Methods of reducing particle formation and compositions formed thereby
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
BR112021015034A2 (en) 2019-02-18 2021-10-05 Eli Lilly And Company THERAPEUTIC ANTIBODY FORMULATION
JP2023535024A (en) 2020-07-23 2023-08-15 オター プロシーナ リミテッド anti-Abeta antibody

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP2727112B2 (en) * 1988-04-26 1998-03-11 コニカ株式会社 Stable peroxidase composition and stable antibody composition
IL91501A (en) 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (en) 1990-07-10 1999-10-15 Cambridge Antibody Tech METHOD FOR PRODUCING SPECIFIC BONDING PAIRS
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DE69233697T2 (en) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Process for the development of binding microproteins
DK1471142T3 (en) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimeric receptor libraries using phagemids
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
JP2966592B2 (en) * 1991-07-20 1999-10-25 萩原 義秀 Stabilized human monoclonal antibody preparation
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
ATE216590T1 (en) * 1995-02-06 2002-05-15 Genetics Inst DRUG FORMULATIONS FOR IL-12
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
AU8755798A (en) 1997-04-04 1998-11-13 Biosite Diagnostics Incorporated Polyvalent and polyclonal libraries
DK0999853T3 (en) 1997-06-13 2003-04-22 Genentech Inc Stabilized antibody formulation
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6710226B1 (en) * 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) * 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
DE1033998T1 (en) 1997-12-03 2001-05-23 Brigham And Women S Hospital B METHOD FOR SUPPRESSING BETA AMYLOID-RELATED CHANGES IN ALZHEIMER
US20050059591A1 (en) * 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US7282570B2 (en) * 1999-04-20 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6787637B1 (en) * 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2000077178A1 (en) * 1999-06-16 2000-12-21 Boston Biomedical Research Institute IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO
BR0012429A (en) 1999-07-15 2002-09-17 Genetics Inst Formulations for il-11
EP1257584B2 (en) 2000-02-24 2013-03-06 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
JP2003516929A (en) * 2000-06-01 2003-05-20 ニユーララブ・リミテツド Prevention and treatment of amyloidogenic diseases
US7700751B2 (en) * 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (en) 2000-12-06 2002-07-02 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
US6916745B2 (en) * 2003-05-20 2005-07-12 Fairchild Semiconductor Corporation Structure and method for forming a trench MOSFET having self-aligned features
DE60229051D1 (en) 2001-04-30 2008-11-06 Lilly Co Eli HUMANIZED ANTIBODIES
EP2165714B1 (en) 2001-04-30 2013-10-23 Eli Lilly And Company Humanized antibodies recognizing the beta-amyloid peptide
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
MXPA04000747A (en) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Stable lyophilized pharmaceutical formulation of igg antibodies.
AU2002324468A1 (en) 2001-08-17 2003-03-03 Eli Lilly And Company Rapid improvement of cognition in conditions related to abeta
WO2003016466A2 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
CA2466034C (en) * 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
AR038568A1 (en) 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004055164A2 (en) * 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
RU2390350C2 (en) * 2003-02-01 2010-05-27 Ньюралаб Лимитед Active immunisation for creating soluble a-beta antibodies
JP4869064B2 (en) * 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド High concentration antibody and protein preparation
TWI374893B (en) * 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
KR101157694B1 (en) * 2003-12-17 2012-06-20 와이어쓰 엘엘씨 Immunogenic peptide carrier conjugates and methods of producing same
EA009559B1 (en) * 2003-12-17 2008-02-28 Элан Фармасьютикелз, Инк. Aβ IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
ES2282940T3 (en) * 2004-02-17 2007-10-16 Tyco Healthcare Group Lp APPLICATION FOR THE APPLICATION OF SURGICAL STAPLES WITH BLOCKING MECHANISM.
US7807804B2 (en) * 2004-10-05 2010-10-05 Wyeth Llc Methods and compositions for improving recombinant protein production
US20060160161A1 (en) * 2004-10-26 2006-07-20 Elan Pharmaceuticals, Inc. Methods for assessing antibodies to neurodegenerative disease-associated antigens
US7625560B2 (en) * 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
AR051800A1 (en) * 2004-12-15 2007-02-07 Wyeth Corp BETA ANTIBODIES USED TO IMPROVE COGNITION
CA2590337C (en) * 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
WO2006066118A2 (en) * 2004-12-15 2006-06-22 Neuralab Limited Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment
WO2006066233A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
AR052469A1 (en) * 2005-01-28 2007-03-21 Wyeth Corp POLYPEPTIDE STABILIZED LIQUID FORMULATIONS
GT200600031A (en) 2005-01-28 2006-08-29 ANTI-BETA ANTIBODY FORMULATION
WO2006138553A2 (en) * 2005-06-17 2006-12-28 Wyeth Methods of purifying fc region containing proteins
WO2009017467A1 (en) * 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CN101970000A (en) * 2007-04-18 2011-02-09 杨森阿尔茨海默氏症免疫治疗公司 Prevention and treatment of cerebral amyloid angiopathy
JO3076B1 (en) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
IT1395574B1 (en) 2009-09-14 2012-10-16 Guala Dispensing Spa DISTRIBUTION DEVICE

Also Published As

Publication number Publication date
UA87549C2 (en) 2009-07-27
CN103768009B (en) 2016-02-24
AU2006211184A1 (en) 2006-08-10
AU2006211184B8 (en) 2011-07-07
KR20070108193A (en) 2007-11-08
JO2740B1 (en) 2014-03-15
EA015147B1 (en) 2011-06-30
AU2006211184B2 (en) 2011-06-16
ES2391407T3 (en) 2012-11-26
TWI398263B (en) 2013-06-11
ZA200705710B (en) 2008-10-29
UY29351A1 (en) 2006-08-31
CN101262884A (en) 2008-09-10
EP1853310A2 (en) 2007-11-14
IL184599A (en) 2011-08-31
WO2006083689A2 (en) 2006-08-10
JP2008528612A (en) 2008-07-31
HK1118723A1 (en) 2009-02-20
EA200701596A1 (en) 2008-02-28
PE20060879A1 (en) 2006-08-19
HK1108132A1 (en) 2008-05-02
DOP2006000021A (en) 2006-08-15
AR052198A1 (en) 2007-03-07
WO2006083689A3 (en) 2006-10-19
TW200700080A (en) 2007-01-01
CN101262884B (en) 2012-10-31
JP4977625B2 (en) 2012-07-18
MY177052A (en) 2020-09-03
HK1196570A1 (en) 2014-12-19
PL1853310T3 (en) 2012-12-31
US7635473B2 (en) 2009-12-22
CA2593122C (en) 2012-03-06
SI1853310T1 (en) 2012-11-30
DK1853310T3 (en) 2012-10-22
IL184599A0 (en) 2007-10-31
US20100166752A1 (en) 2010-07-01
CN103768009A (en) 2014-05-07
EP1853310B1 (en) 2012-08-01
US20060193850A1 (en) 2006-08-31
NZ556393A (en) 2010-02-26
US8318164B2 (en) 2012-11-27
NO20073305L (en) 2007-08-24
EP2392353A1 (en) 2011-12-07
MX2007009050A (en) 2008-04-04
BRPI0607039A2 (en) 2009-08-25
EA021507B1 (en) 2015-07-30
PT1853310E (en) 2012-10-22
KR101188060B1 (en) 2012-10-24
GT200600031A (en) 2006-08-29
EA201100180A1 (en) 2011-10-31

Similar Documents

Publication Publication Date Title
CA2593122A1 (en) Anti a beta antibody formulation
US11873343B2 (en) Pharmaceutical formulations comprising anti-RANKL antibodies and an aromatic amino acid comprising a phenyl or an indole
EP2991678B1 (en) Anti-il-4/anti-il-13 bispecific antibody formulations
EP2331078B1 (en) Lyophilized formulations of engineered anti-il-23p19 antibodies
CN110869002A (en) Stable formulations of programmed death receptor 1(PD-1) antibodies and methods of use thereof
EP3618855A1 (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
RU2007124933A (en) STABILIZED LIQUID POLYPEPTIDE COMPOSITIONS
JP2008528638A5 (en)
EA031436B1 (en) Aqueous pharmaceutical composition, pre-filled syringe comprising same and use of the composition in treating autoimmune diseases
EP4218814A2 (en) Stabilized formulations containing anti-pcsk9 antibodies
WO2018204343A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
KR102385802B1 (en) Liquid formulation comprising gm-csf neutralizing compound
JP6400595B2 (en) Anti-HER2 antibody preparation
US20210205453A1 (en) Csf-1r antibody formulation
US20200231698A1 (en) Bispecific antibody formulation
US20150225479A1 (en) Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations
US20230174638A1 (en) Formulations of anti-il-33 antibodies
WO2018179138A1 (en) Antibody-containing liquid preparation
US20170137535A1 (en) Anti-factor d antibody formulations
JP2023532203A (en) Activin A antibody preparation and method of use thereof
KR20220028972A (en) Stable Pharmaceutical Formulation
CN116803420A (en) Bifunctional protein pharmaceutical composition targeting PD-1 and TGF beta and application thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190128